Who
Mary C. Beckerle
Director
Company insider
Files Form 4 as: Director, Exelixis; Director, Johnson & Johnson; Director, Huntsman.
In numbers
- Trades disclosed
- 55
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $4.2M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 5 May 2011
- Last trade
- 10 Aug 2026
- Last filed
- 12 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Aug 2026filed 12 Aug 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $527K9,812 at $53.66 | filing |
| 10 Aug 2026filed 12 Aug 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $527K9,812 at $53.66 | filing |
| 27 May 2026filed 29 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —8,367 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —8,367 at $0.00 | filing |
| 7 May 2026filed 8 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code M | $90K3,856 at $23.24 | filing |
| 7 May 2026filed 8 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $374K7,712 at $48.45 | filing |
| 7 May 2026filed 8 May 2026 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,856 at $0.00 | filing |
| 7 May 2026filed 8 May 2026 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,856 at $0.00 | filing |
| 7 May 2026filed 8 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code M | $90K3,856 at $23.24 | filing |
| 7 May 2026filed 8 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $374K7,712 at $48.45 | filing |
| 23 Apr 2026filed 27 Apr 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —975 at $0.00 | filing |
| 23 Apr 2026filed 27 Apr 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —975 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | HUN HuntsmanChemicals | SEC FORM 4 Code A | —12,434 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | HUN HuntsmanChemicals | SEC FORM 4 Code A | —12,434 at $0.00 | filing |
| 11 Nov 2025filed 13 Nov 2025 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,784 at $0.00 | filing |
| 11 Nov 2025filed 13 Nov 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Code M | $134K5,784 at $23.24 | filing |
| 11 Nov 2025filed 13 Nov 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $243K5,784 at $42.03 | filing |
| 11 Nov 2025filed 13 Nov 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $789K18,838 at $41.90 | filing |
| 29 May 2025filed 30 May 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —9,812 at $0.00 | filing |
| 24 Apr 2025filed 28 Apr 2025 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —1,316 at $0.00 | filing |
News
Citizens Jmp Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) StockEXEL · tickerreport.com · 21 Oct 2026Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law FirmEXEL · prnewswire.com · 13 Oct 2026
0 headlines in the last 90 days name Mary C. Beckerle; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.